Serum müllerian-inhibiting substance levels during normal menstrual cycles

Cook, Christine L.; Siow, Yong; Taylor, Susan; Fallat, Mary E.

doi:10.1016/s0015-0282(99)00639-1

Cited by 230 publications

(152 citation statements)

References 6 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…In this way, it may be a more sensitive predictor of ovarian reserve than other markers, such as AFC and inhibin B, which detect more mature primordial follicles. Antimullerian hormone has a relatively stable expression over the menstrual cycle (Cook et al, 2000;La Marca et al, 2006). This would explain why serum AMH levels were mostly unchanged in our study following the G-test, a phenomenon detected in other studies (van Rooij et al, 2002;Pastor et al, 2005).…”

Section: P<001supporting

confidence: 64%

Predictors of ovarian reserve in young women with breast cancer

et al. 2007

View full text Add to dashboard Cite

Ovarian reserve can be diminished following treatment for breast cancer. This study evaluated biochemical and biophysical parameters of ovarian reserve in these patients. Biochemical and biophysical tests of ovarian reserve were performed simultaneously in young (age 22 -42 years), regularly menstruating women with breast cancer (n ¼ 22) and age-matched controls (n ¼ 24). All tests were performed before (baseline) and after transient ovarian stimulation in the early follicular phase. Patients were recruited both before and after completion of chemotherapy, with some patients being followed up prospectively. Serum samples were analysed for follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol (E 2 ), inhibins A and B, and antimullerian hormone (AMH). Biophysical (ultrasound) tests included ovarian volume, antral follicle count (AFC), ovarian stromal blood flow and uterine dimensions. Significant differences were revealed (when compared with the controls) for basal FSH (11.3271

show abstract

Section: P<001supporting

confidence: 64%

Predictors of ovarian reserve in young women with breast cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Firstly, serum AMH has been shown to be the most sensitive predictor of ovarian response to COH compared to serum FSH, inhibin B, oestradiol, antral follicle count and ovary volume [8,9]. Secondly, unlike serum FSH, inhibin B and oestradiol levels, serum AMH levels appear to be relatively stable throughout the menstrual cycle [29][30][31], making assessment of ovarian reserve possible at any stage of the cycle. Thirdly, serum AMH levels have the greatest reproducibility with the least variation between cycles of any of the serum markers of ovarian reserve [32].…”

Section: Discussionmentioning

confidence: 99%

Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

Lekamge

Lane

Gilchrist³

et al. 2008

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose This retrospective study was carried out to evaluate whether increasing the starting dose of FSH stimulation above the standard dose of 150 IU/day in patients with low predicted ovarian reserve can improve IVF outcomes. Method A total of 122 women aged less than 36 years in their first cycle of IVF were identified as having likely low ovarian reserve based on a serum AMH measurement below 14 pmol/l. Thirty five women were administered the standard dose of 150 IU/day FSH, while the remaining 87 received a higher starting dose (200-300 IU/day FSH). There were no significant differences in age, BMI, antral follicle count, serum AMH, FSH or aetiology of infertility between the two dose groups.Results No significant improvement in oocyte and embryo yield or pregnancy rates was observed following an upward adjustment of FSH starting dose. While increasing the dose of FSH above 150 IU/day did not produce any adverse events such as OHSS, it did consume an extra 1,100 IU of FSH per IVF cycle. ConclusionThe upward FSH dose adjustment in anticipation of low ovarian reserve can not be advocated as it is both expensive and of no proven clinical value.

show abstract

“…AMH levels changes very little during the menstrual cycle. This feature enables the use of AMH in clinics [28]. AMH may be used as a marker to follow the granulose cell tumors, recognize puberta peroxy and delayed puberta and to evaluate female gonadal function in prepubertal and pubertal girls.…”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian Hormone (AMH) in Adults with Polycystic Ovary Syndrome and Pregnants

Sarıyıldız¹

2016

Eu Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Çalışmada puberta öncesi ve sonrası sağlıklı kız çocukları; over kistli yetişkinler ile hamilelerde anti-Müllerian hormonu AMH ve bazı biyokimyasal parametrelerin karşılaştırılmaları yoluyla değişimin saptanması amaç-landı. Gereç ve Yöntem: Bu çalışma Dr. Faruk Sükan Doğum ve Çocuk Hastanesinin polikliniklerine başvuran ve herhangi bir metabolik hastalığı olmayan dört grupta yer alan toplam100 katılımcı üzerinde gerçekleştirildi. Çalış-maya 7-12 yaş arası prepubertal dönemdeki kız çocuklarından (n=25), 18-24 yaş arası over kist sendromlu (n=25), 18-25 yaş arası hamileliğin 1.trimesterindeki kadınlardan (n=25) ve 18-24 yaş arası (n=25) sağlıklı bireyler kontrol grubu olarak alındı. Bulgular: Prepubertal dönemde (7-12 yaş arası) 25 kız çocuğu ile kontrol grubu(18-24 yaş arası) 25 kız çocuğu AMH değerle-ri sırasıyla 3,62 pg/dl; 3,60 pg/dl olarak bulundu (p═0,7636). Çalışmada over kist sendromlu grubun (18-24 yaş arası) AMH seviyesi 4,11 pg/dL (p═0,8690) olarak bulundu. Tartışma: AMH'nin klinik çalışmalarda over rezervinin tespit edilmesinde kullanılması infertilite tedavisinin ve yardımcı üreme tekniklerinin başarısını önceden tahmin etme ve PKOS'un teşhisi anlamında avantajlar sağlamaktadır. Anahtar KelimelerAnti-Müllerian Hormon; Over Kisti; Hamilelik; Fertilite AbstractAim: The aim of the study was to investigate serum anti-Müllerian hormone (AMH) and various biochemical parameter levels in healthy females before and after puberta, adults with polycystic ovary syndrome and pregnant women. Material and Method: The present study was performed on 100 female volunteers in four groups who applied to the polyclinic in Dr. Faruk Sukan maternal and children hospital and who had no metabolic syndrome.The groups were classified as: group 1: 7-12 years of age, prepubertal period (n=25); group 2: 18-25 years of age, pregnant females in the first trimester (n=25); group 3: 18-24 years of age, suffering from ovarian cysts (n=25); group 4: 18-24 years of age postpubertal as a control group (n=25). Results: The levels of AMH were found in prepubertal females (age 7-12) and the control group (age 18-24) as 3.62 pg/dl and 3.60 pg/dl, respectively (p=0.7636). The levels of AMH were 4.11 pg/dl (p=0.8690) in the women suffering from polycystic ovary syndrome. Discussion: The use of AMH in the measurement of ovarian reserve in clinical trials provides an advantage in early diagnosis of infertility and polycystic ovary syndrome (PCOS).

show abstract

Serum müllerian-inhibiting substance levels during normal menstrual cycles

Cited by 230 publications

References 6 publications

Predictors of ovarian reserve in young women with breast cancer

Predictors of ovarian reserve in young women with breast cancer

Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

Anti-Müllerian Hormone (AMH) in Adults with Polycystic Ovary Syndrome and Pregnants

Contact Info

Product

Resources

About